The Effect of Tegaserod on Symptoms and Quality of Life in Korean Women with Irritable Bowel Syndrome with Constipation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김용성 | - |
dc.contributor.author | Jae Myung Park | - |
dc.contributor.author | 최창환 | - |
dc.contributor.author | 이동호 | - |
dc.contributor.author | Hee Jung Son | - |
dc.contributor.author | 성인경 | - |
dc.contributor.author | Jeong Jo Jeong | - |
dc.contributor.author | 이준성 | - |
dc.contributor.author | 심기남 | - |
dc.contributor.author | 이광재 | - |
dc.contributor.author | 최석채 | - |
dc.contributor.author | 홍수진 | - |
dc.date.accessioned | 2021-08-12T07:34:26Z | - |
dc.date.available | 2021-08-12T07:34:26Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 2093-0879 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18562 | - |
dc.description.abstract | Introduction Tegaserod has been used for treatment of irritable bowel syndrome (IBS) but there is no data regarding its effect on Korean patients. The aim of this study was to evaluate the effect of tegaserod on symptoms and quality of life (QOL) in Korean female IBS patients with constipation and to evaluate the usefulness of the IBS-QOL in clinical study. Methods A prospective, open labeled, multicenter study was performed. Female patients fulfilling Rome II criteria for IBS received 6 mg of tegaserod twice a day for 4 weeks. The efficacy on IBS symptoms and QOL was assessed using 7-point scaled symptom questionnaire and IBS-QOL questionnaire, respectively. Results A total of 81 female patients (range 18-73 years of age) were enrolled in this study. Tegaserod therapy significantly reduced the overall symptom scores after 4 weeks (p<0.01). The improved symptoms included abdominal discomfort or pain, hard or lumpy stool, straining during a bowel movement, feeling of incomplete bowel movement, and abdominal fullness or bloating. The IBS-QOL of responders to tegaserod treatment was also significantly improved after 4 weeks (p<0.01). Furthermore, improvement of symptom scores significantly correlated with improvement of the IBS-QOL scores (r=-0.60, p<0.001). Conclusions Tegaserod 6 mg given twice daily improved the QOL as well as the bowel symptoms in Korean female IBS patients with constipation. The IBS-QOL can be used as a reliable end-point in clinical study.(J Neurogastroenterol Motil 2010;16:61-70) | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한소화기 기능성질환∙운동학회 | - |
dc.title | The Effect of Tegaserod on Symptoms and Quality of Life in Korean Women with Irritable Bowel Syndrome with Constipation | - |
dc.title.alternative | The Effect of Tegaserod on Symptoms and Quality of Life in Korean Women with Irritable Bowel Syndrome with Constipation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 이준성 | - |
dc.contributor.affiliatedAuthor | 홍수진 | - |
dc.identifier.bibliographicCitation | Journal of Neurogastroenterology and Motility (JNM), v.16, no.1, pp.61 - 70 | - |
dc.relation.isPartOf | Journal of Neurogastroenterology and Motility (JNM) | - |
dc.citation.title | Journal of Neurogastroenterology and Motility (JNM) | - |
dc.citation.volume | 16 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 61 | - |
dc.citation.endPage | 70 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001418418 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Tegaserod | - |
dc.subject.keywordAuthor | Irritable bowel syndrome | - |
dc.subject.keywordAuthor | Quality of life | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.